Stock Ratings / Health Care / MXCT / earnings

NRC (65) OABI (38) ONMD (29) ABSI (45) ⌘ Pro Terminal →

MaxCyte Inc. (MXCT) Next Earnings Date & Expected ±12.5% Move

$1.73 +1.17% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.73

MaxCyte Inc. (MXCT) carries a Roarable Rating of E (Strong Sell) with 30/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (30/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $178.5M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.73 (+0.02%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (30/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.6% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-12.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MXCT)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (30/100 Composite)

🔍 WHY MXCT SCORES 30/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+9/20 pts (30% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+9/20 pts (30% of score)

FRED Regime × Technicals: 93% of 52W Range • RSI-14 at 65.4 (BULLISH MOMENTUM)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$1.01+28.7% Next Q

Q2 (-2Q)

Grade E$1.30+7.7% Next Q

Q3 (-1Q)

Grade E$1.40+23.6% Next Q

Current

Grade E$1.73-9.6% Hist 90D α

Trajectory: E (22) → E (30)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a MXCT Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While MXCT currently carries a cautious 30/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.26) and Max Pain ($1.82) forces dealer call-delta covering toward $1.90.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $MXCT• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “MXCT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 30%NO 70%Trade / Inspect Odds →

NEXT EST. WINDOW: Dec 30, 2026 (~58 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.22 Expected Swing

MODEL EARNINGS SETUP GAUGE

MXCT Quantitative Pre-Earnings Setup: 30/100

Trailing EPS: $4.25 • YoY Revenue Growth: -5.7%

Model Bullish Setup (30/100)Model Risk Weight (70/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$21.0M	-$44.6M	-$36.2M	98%
FY 2024	2024-12-31	$22.2M	-$41.1M	-$29.3M	98%
FY 2023	2023-12-31	$19.5M	-$37.9M	-$21.7M	92%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring MXCT)

✓Walkthrough of MXCT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

MXCT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +96.59%📐 HORIZONTAL RANGE

2026-10-30O $1.71H $1.73L $1.50C $1.73VOL 963.6K

RES: $2.01SUP: $0.83SMA50: $1.26SMA200: $1.06

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

MXCT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 MXCT Butterfly Map → + Track MXCT →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -5.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on MXCT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for MXCT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for MXCT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MXCT)

Health Care Rank #942 of 1016 ⚔️ NRC vs MXCT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (MXCT vs. NRC, OABI, ONMD, ABSI)

Industry: Biotechnology: Commercial Physical & Biological Resarch (12 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, MaxCyte Inc. (MXCT) ranks #942 by composite RQD confidence (30/100, grade E) and #592 by equity capitalization ($178.5M). Within this direct 5-issuer industry benchmark cohort, NRC leads on earnings valuation at 44.8x trailing P/E, while NRC leads on capital efficiency and profitability with 21.0% ROIC and — gross margin. NRC currently holds the highest overall quantitative score in the immediate peer group at 65/100 (C) compared with MXCT at 30/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
MXCT ACTIVE MaxCyte Inc.	E	30/100	—	96.0%	-27.1%	+1.17%	$178.5M	Benchmark Subject
NRC NRC Health	C	65/100	44.8x	—	21.0%	+0.09%	$519.6M	/nrc-vs-mxct →
OABI OmniAb Inc.	D-	38/100	—	—	-22.6%	-0.95%	$760.4M	/oabi-vs-mxct →
ONMD OneMedNet Corp (Class A)	E	29/100	—	-30.0%	-35.0%	-2.02%	$26.3M	/onmd-vs-mxct →
ABSI Absci Corporation	D	45/100	—	—	-35.0%	+1.85%	$2.08B	/absi-vs-mxct →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001287098

In its most recent audited fiscal period (FY2025, filed 2025-12-31), MaxCyte Inc. (MXCT) reported GAAP revenue of $21.0M (-5.7% vs. FY2024 revenue of $22.2M , and +7.5% cumulative change since FY2023) , GAAP net income of -$44.6M, operating cash flow of -$34.4M, and free cash flow of -$36.2M (-23.6% YoY). On the balance sheet, MXCT closed FY2025 with $202.5M in total assets against $0 in total debt (Altman Z-Score: 1.52, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$21.0M	-$44.6M	-$34.4M	-$36.2M	$202.5M	—
FY2024 (FY)	2024-12-31	$22.2M	-$41.1M	-$27.6M	-$29.3M	$239.5M	—
FY2023 (FY)	2023-12-31	$19.5M	-$37.9M	-$21.7M	-$21.7M	—	—

3. MXCT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is MXCT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, MaxCyte Inc. (NASDAQ: MXCT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $1.73 (+1.17% 1D, market cap $178.5M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, MXCT ranks #942 in composite RQD confidence.

How does MXCT compare to NRC and OABI in the Health Care sector?

Within the Health Care sector (Biotechnology: Commercial Physical & Biological Resarch), MXCT carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of 96.0%, and ROIC of -27.1%. By comparison, NRC (NRC Health) holds a C grade (65/100 RQD, P/E 44.8x, ROIC 21.0%, cap $519.6M) and OABI (OmniAb Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -22.6%, cap $760.4M). Among the 5-stock peer group, NRC leads on earnings multiple (44.8x) while NRC leads on capital efficiency (21.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for MXCT?

Per MXCT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001287098), MaxCyte Inc. generated $21.0M in revenue (-5.7% YoY), -$44.6M in net income, and -$36.2M in free cash flow against $202.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is MXCT trading relative to its 50-day, 200-day, and 52-week technical levels?

MXCT last traded at $1.73 (+1.17% on volume of 1,142,252 shares), positioning the stock +37.30% above its 50-day simple moving average ($1.26) and +63.21% above its 200-day simple moving average ($1.06). Across its 52-week range of $0.64 to $1.81, MXCT sits at the 93.2% percentile with a 14-day RSI of 65.4 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($1.51 to $1.95).